Myriad Genetics (NASDAQ:MYGN) Releases FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.070-0.110 for the period, compared to the consensus estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MYGN shares. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Piper Sandler cut their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. UBS Group began coverage on Myriad Genetics in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price objective for the company. Finally, Bank of America dropped their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a report on Friday, December 13th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $24.27.

Myriad Genetics Stock Performance

NASDAQ MYGN opened at $13.68 on Wednesday. Myriad Genetics has a twelve month low of $12.87 and a twelve month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.25 billion, a P/E ratio of -10.52 and a beta of 1.89. The company’s 50-day simple moving average is $15.05 and its 200 day simple moving average is $22.17.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.